Low-dose hydrocortisone treatment for patients with septic shock: A pilot study comparing 3 days with 7 days

Respirology

Volumn 16, Issue 7, 2011, Pages 1088-1095

  Huh, Jin Won ^a   Choi, Hye Sook ^b   Lim, Chae Man ^a   Koh, Younsuck ^a   Oh, Yeon Mok ^a   Shim, Tae Sun ^a   Lee, Sang Do ^a   Kim, Woo Sung ^a   Kim, Dong Soon ^a   Hong, Sang Bum ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Dongguk University College of Medicine   (South Korea)

Author keywords

adrenal insufficiency; hydrocortisone; mortality; septic shock; shock reversal

Indexed keywords

CORTICOSTEROID; DOPAMINE; ETOMIDATE; GLUCOSE; HYDROCORTISONE; HYPERTENSIVE FACTOR; INSULIN; NORADRENALIN;

ADRENAL INSUFFICIENCY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; BRAIN EDEMA; BRONCHOSPASM; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFECT; FEMALE; FLUID RESUSCITATION; FLUID THERAPY; GLUCOSE BLOOD LEVEL; HUMAN; INTENSIVE CARE UNIT; INTERSTITIAL LUNG DISEASE; LENGTH OF STAY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY INFECTION; SEPTIC SHOCK; SIDE EFFECT; SURVIVAL; TREATMENT DURATION; TREATMENT WITHDRAWAL;

ADRENAL INSUFFICIENCY; ANTI-INFLAMMATORY AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROCORTISONE; INTENSIVE CARE; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; SEPSIS; SHOCK, SEPTIC; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 80053306142     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2011.02018.x     Document Type: Article

References (31)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al,. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 2001; 29: 1303-10. (Pubitemid 32641789)
2. Moreno R, Afonso S, Fevereiro T,. Incidence of sepsis in hospitalized patients. Curr. Infect. Dis. Rep. 2006; 8: 346-50. (Pubitemid 44445707)
3. Annane D, Aegerter P, Jars-Guincestre MC, et al,. Current epidemiology of septic shock: the CUB-Rea Network. Am. J. Respir. Crit. Care Med. 2003; 168: 165-72. (Pubitemid 36920969)
4. Buckingham JC,. Fifteenth Gaddum Memorial Lecture December 1994. Stress and the neuroendocrine-immune axis: the pivotal role of glucocorticoids and lipocortin 1. Br. J. Pharmacol. 1996; 118: 1-19. (Pubitemid 26131243)
5. Zeni F, Freeman B, Natanson C,. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit. Care Med. 1997; 25: 1095-100. (Pubitemid 27310241)
6. Wheeler AP, Bernard GR,. Treating patients with severe sepsis. N. Engl. J. Med. 1999; 340: 207-14. (Pubitemid 29063218)
7. Hotchkiss RS, Karl IE,. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 2003; 348: 138-50. (Pubitemid 36056721)
8. Annane D, Sebille V, Charpentier C, et al,. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862-71.
9. Sligl WI, Milner DA Jr, Sundar S, et al,. Safety and efficacy of corticosteroids for the treatment of septic shock: a systematic review and meta-analysis. Clin. Infect. Dis. 2009; 49: 93-101.
10. Annane D, Bellissant E, Bollaert PE, et al,. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009; 301: 2362-75.
11. Minneci PC, Deans KJ, Eichacker PQ, et al,. The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis. Clin. Microbiol. Infect. 2009; 15: 308-18.
12. Sprung CL, Annane D, Keh D, et al,. Hydrocortisone therapy for patients with septic shock. N. Engl. J. Med. 2008; 358: 111-24.
13. Briegel J, Forst H, Haller M, et al,. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit. Care Med. 1999; 27: 723-32. (Pubitemid 29218204)
14. Oppert M, Schindler R, Husung C, et al,. Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit. Care Med. 2005; 33: 2457-64. (Pubitemid 41682095)
15. Dellinger RP, Levy MM, Carlet JM, et al,. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 2008; 34: 17-60.
16. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med. 1992; 20: 864-74.
17. Annane D, Sebille V, Troche G, et al,. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000; 283: 1038-45. (Pubitemid 30112218)
18. Marik PE, Zaloga GP,. Adrenal insufficiency during septic shock. Crit. Care Med. 2003; 31: 141-5. (Pubitemid 36151163)
19. Garner JS, Jarvis WR, Emori TG, et al,. CDC definitions for nosocomial infections, 1988. Am. J. Infect. Control 1988; 16: 128-40.
20. Vincent JL, de Mendonca A, Cantraine F, et al,. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on 'sepsis-related problems' of the European Society of Intensive Care Medicine. Crit. Care Med. 1998; 26: 1793-800. (Pubitemid 28527688)
21. Gray RJ,. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann. Stat. 1988; 116: 1141-54.
22. Dellinger RP, Levy MM, Carlet JM, et al,. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit. Care Med. 2008; 36: 296-327.
23. Bone RC, Fisher CJ Jr, Clemmer TP, et al,. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 1987; 317: 653-8. (Pubitemid 17138189)
24. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. The Veterans Administration Systemic Sepsis Cooperative Study Group. N. Engl. J. Med. 1987; 317: 659-65.
25. Keh D, Boehnke T, Weber-Cartens S, et al,. Immunologic and hemodynamic effects of 'low-dose' hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am. J. Respir. Crit. Care Med. 2003; 167: 512-20.
26. Russell JA,. Management of sepsis. N. Engl. J. Med. 2006; 355: 1699-713. (Pubitemid 44583960)
27. Lefering R, Neugebauer EA,. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit. Care Med. 1995; 23: 1294-303.
28. Cronin L, Cook DJ, Carlet J, et al,. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit. Care Med. 1995; 23: 1430-9.
29. Sprung CL, Caralis PV, Marcial EH, et al,. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N. Engl. J. Med. 1984; 311: 1137-43. (Pubitemid 14012580)
30. Rivers E, Nguyen B, Havstad S, et al,. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 2001; 345: 1368-77.
31. Marik PE, Pastores SM, Annane D, et al,. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit. Care Med. 2008; 36: 1937-49.